#United States #Las Vegas #Medtronic #URO #Hugo

Medtronic's Expand URO: A Leap Forward in Robotic Surgery

Medtronic, a global leader in healthcare technology, has officially announced a significant achievement in the field of robotic-assisted urologic surgery. The Expand URO clinical trial stands out as the largest Investigational Device Exemption (IDE) clinical study for this type of surgery in the U.S., and its findings were presented at the esteemed American Urological Association (AUA) annual meeting in Las Vegas.

The primary endpoints assessing safety and efficacy were not only met but exceeded expectations, establishing Medtronic's Hugo™ robotic-assisted surgery (RAS) system as a promising solution for urologic procedures. The study involved 137 patients and demonstrated a 98.5% surgical success rate, greatly surpassing the previously set performance goal of 85%. Formulated with rigorous premarket requirements, the study confirms that the Hugo RAS system performs effectively in complex urologic scenarios.

About the Expand URO Clinical Study

The Expand URO trial enrolled a diverse cohort of approximately 137 patients, all classified under the American Society of Anesthesiologists (ASA) category ≥3, indicating they had significant systemic disease impacting their overall health. The study was conducted across six hospitals, with eleven skilled surgeons performing a range of urologic procedures, including:

• - Prostatectomies (n=55) for prostate cancer
• - Nephrectomies (n=53) for renal tumors
• - Cystectomies (n=29) for bladder tumors

Measured against a backdrop of stringent FDA premarket protocols, the trial ensured independent event adjudication and excellent follow-up compliance. Remarkably, around 98% of patients completed the required 30-day follow-up, indicating a robust operational framework.

Safety Outcomes

Safety was a fundamental concern during the clinical trial, and the results were telling. The occurrence of severe complications (grade 3 or higher) was well below predetermined performance goals, showing:

• - 3.7% for prostatectomies
• - 1.9% for nephrectomies
• - 17.9% for cystectomies

These rates are significantly lower than the FDA benchmarks of 20%, 20%, and 45%, respectively, underscoring the safety of the Hugo RAS system for patients undergoing these critical procedures.

Effectiveness Achievements

In terms of effectiveness, achieving a 98.5% surgical success rate reflects the high caliber of the technology and the surgical expertise involved. Only two conversions from robotic to traditional methods occurred during the study: one was device-related, and another stemmed from patient-specific anatomical issues.

Implications of the Study Findings

Dr. Michael R. Abern, the national principal investigator of the study and a prominent urologic surgeon, expressed his insights, stating that the results aligned well with published literature in robotic-assisted surgery, pointing towards a paradigm shift in urologic surgical practices. This groundbreaking study paves the way for a future where robotic technology becomes an integral part of clinical care—enhancing patient outcomes and operational efficiency.

In light of these findings, James Porter, M.D., Chief Medical Officer at Medtronic, emphasized that the Expand URO study delivers crucial evidence supporting the clinical application of the Hugo RAS system. Medtronic's vision aims to offer U.S. surgeons finally a much-anticipated choice in robotic technology, empowering them to deliver optimized care.

Next Steps: FDA Submission and Global Use

Following the successful completion of the Expand URO trial, Medtronic has submitted the Hugo RAS system to the U.S. Food and Drug Administration (FDA) for a urologic indication in early 2025. This submission not only marks a significant milestone for Medtronic but also aims to facilitate the entry of the Hugo system into the U.S. market—currently recognized as the largest robotic surgery market globally.

The Hugo RAS system is already in clinical use in over 25 countries and has gained substantial traction through numerous published studies, demonstrating its versatility and efficacy in various surgical contexts beyond urology.

In conclusion, the Expand URO clinical trial by Medtronic serves as a definitive step towards transforming robotic surgery, adhering to the principles of minimally invasive techniques and innovative healthcare solutions. As Medtronic looks to navigate the landscape of surgical robotics, the findings from this study will be pivotal in shaping future protocols and tools for patient care.